首页> Therapeutic advances in neurological disorders> Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

导出 OA

翻译打印收藏纠错

第一作者： Peter,Rieckmann

第一单位： Center for Clinical Neuroplasticity, Medical Park Loipl, Bischofswiesen, Germany.

作者： Peter,Rieckmann ^[1] ; Diego,Centonze ^[2] ; Gavin,Giovannoni ^[3] ; Le H,Hua ^[4] ; Celia,Oreja-Guevara ^[5] ; Daniel,Selchen ^[6] ; Per Soelberg,Sørensen ^[7] ; Patrick,Vermersch ^[8] ; Heinz,Wiendl ^[9] ; Hashem,Salloukh ^[10] ; Bassem,Yamout ^[11]

作者单位： Center for Clinical Neuroplasticity, Medical Park Loipl, Bischofswiesen, Germany. ^[1] Unit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli (IS), Italy. ^[2] Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ^[3] Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. ^[4] Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain. ^[5] Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. ^[6] Danish Multiple Sclerosis Center, Department of Neurology, University of Copenhagen and Rigshospitalet, Copenhagen, Denmark. ^[7] Université de Lille, INSERM-U1172, Centre Hospitalier Universitaire de Lille, Fédératif Hospitalo-Universitaire Precise, Lille, France. ^[8] Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany. ^[9] Ares Trading SA, Eysins, Switzerland (an affiliate of Merck KGaA). ^[10] Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE. ^[11]

关键词 COVID-19 cladribine tablets consensus disease-modifying drugs expert opinion relapsing multiple sclerosis vaccination

DOI 10.1177/17562864211058298

PMID 34899987

发布时间 2025-05-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交